Condition
Cognition Function
Total Trials
3
Recruiting
0
Active
0
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
67%
2 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 4 (2)
Trial Status
Completed1
Enrolling By Invitation1
Terminated1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT07154147Phase 4Completed
Oral vs IV Sedation for Cataract Surgery in Older Adults
NCT07074704Not ApplicableEnrolling By Invitation
tACS to Improve Negative Symptoms & Cognition in Long-term Hospitalized Schizophrenia Patients.
NCT03784222Phase 4Terminated
Effects on Social and Cognition Functions of Blonanserin in First Episode Schizophrenia Patients
Showing all 3 trials